Download or read book The Changing Economics of Medical Technology written by Institute of Medicine and published by National Academies Press. This book was released on 1991-02-01 with total page 225 pages. Available in PDF, EPUB and Kindle. Book excerpt: Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.
Download or read book Economics of the Pharmaceutical and Medical Device Industry written by Ramesh Bhardwaj and published by Taylor & Francis. This book was released on 2024-08-01 with total page 251 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides a comprehensive examination of the pharmaceutical and medical device industry, including analysis of its current trade and innovation strategies. Opening with a survey of the global pharmaceutical and medical device industry, Bhardwaj outlines the growing trade and trade interdependence among countries in the global supply chain. He adopts a trade competitiveness approach to analyze patterns of product specialization and examines the drug discovery process and its challenges in translating bioscientific knowledge into lifesaving products. Bhardwaj argues that further economic integration, collaborative R&D, and digital technologies may help accelerate productivity and address global challenges of escalating drug costs, neglected tropical diseases (NTDs), and pandemic risks. The book also considers how the industry may further green its supply chain, and thus contribute to SDG Goals 3 (Good Health and Wellbeing) and 12 (Responsible Consumption and Production), before closing on a review of China and India, major players who have the potential to become drivers of low-cost medical products and innovations. With its evidence-based analysis, this book will be of great interest to researchers in pharmaceutical studies, supply chain management, global health, and health economics, as well as policymakers and professionals interested in the global issues facing the industry.
Download or read book Pharmaceutical Economics and Policy written by Stuart O. Schweitzer and published by Oxford University Press. This book was released on 2018-05-01 with total page 433 pages. Available in PDF, EPUB and Kindle. Book excerpt: Pharmaceuticals constitute a relatively small share of the total healthcare expenditure in most developed economies, and yet they play a critical role in the ongoing debate over how best to advance, improve, and afford healthcare. Despite this, and perhaps because of this, the industry has had, for many years, an outsized claim to fame and controversy, praise and criticisms, support and condemnation. Unfortunately, many participants in the debate do not fully understand the complexities of the industry and its role in the overall healthcare system. The analytical tools of economics provide a strong foundation for a better understanding of the dynamics of the pharmaceutical industry, its contribution to health and healthcare, its dual and often conflicting priorities of affordability and innovation, as well as the various private and public policy initiatives directed at the sector. This third edition of a uniquely comprehensive and balanced examination of the industry includes several new chapters on important topics such as the full-fledged generics sector, the arrival of biosimilars or generic biological drugs, the global consolidation of manufacturers, the evolving reimbursement landscape, and the emergence of the world's most populous nations, such as China, India, and Brazil, as both suppliers and consumers of pharmaceutical products. Other chapters have been fully rewritten or extensively updated, covering such important topics as the cost efficiency of research and development, pace of new innovations, economic evaluation and value-based pricing of drugs, and public and private interventions in the industry.
Download or read book Pharmaceutical Economics and Policy written by Stuart O. Schweitzer and published by Oxford University Press. This book was released on 2007 with total page 351 pages. Available in PDF, EPUB and Kindle. Book excerpt: Publisher description
Download or read book The Economics of Medical Technology written by Kristian Bolin and published by Emerald Group Publishing. This book was released on 2012-09-05 with total page 211 pages. Available in PDF, EPUB and Kindle. Book excerpt: Includes various aspects of the process of treating disease (such as pharmaceuticals, medical devices, and surgical procedures) is important for individual health and, consequently, also for general welfare. This title provides theoretical and empirical evidence about the market for medical technology.
Download or read book Economics of the Pharmaceutical Industry written by John W. Egan and published by Greenwood. This book was released on 1982 with total page 232 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Pharmaceutical Economics and Public Policy written by Ronald Vogel and published by CRC Press. This book was released on 2007-07-25 with total page 282 pages. Available in PDF, EPUB and Kindle. Book excerpt: Get a comprehensive explanation of the key economic concepts on how the pharmaceutical market functions The pharmaceutical industry has come under intense public scrutiny for the perception of product prices being too high and for concerns about research and development spending. Pharmaceutical Economics and Public Policy carefully explains the fundamentals of pharmaceutical economics while examining spending, costs, rates of return, and policies affecting the industry. This text provides a comprehensive economic analysis of the most important dimensions of the pharmaceutical market with easy-to-understand analysis of the implications of public policy. Key economic concepts necessary for understanding how the pharmaceutical market functions are clearly explained in detail. Though it is a manufacturing industry, the pharmaceutical industry has several economic aspects that make it fundamentally different from any other. Pharmaceutical Economics and Public Policy takes these sometimes confusing and difficult economic aspects within this unique industry and makes them understandable. The book is carefully referenced and includes numerous figures and tables to clearly present data. Topics in Pharmaceutical Economics and Public Policy include: policymaking—self-interest vs. public interest a pharmaceutical market overview empirical data on cost effectiveness of pharmaceutical use the economics and politics of the regulatory process the economics of patent policies pharmaceutical cost structure why price discrimination occurs in patented pharmaceuticals governmental price controls R&D expenditures sales and marketing expenditures rates of profitability in the pharmaceutical industry mergers and acquisitions and the connection to higher risk levels the future of the pharmaceutical industry Pharmaceutical Economics and Public Policy is an invaluable resource for educators, graduate students, policymakers, legislators, policy analysts, government agencies, and trade associations involved with pharmaceuticals.
Download or read book The Oxford Handbook of the Economics of the Biopharmaceutical Industry written by Patricia M. Danzon and published by Oxford University Press. This book was released on 2012-04-12 with total page 618 pages. Available in PDF, EPUB and Kindle. Book excerpt: The biopharmaceutical industry has been a major driver of technological change in health care, producing unprecedented benefits for patients, cost challenges for payers, and profits for shareholders. As consumers and companies benefit from access to new drugs, policymakers around the globe seek mechanisms to control prices and expenditures commensurate with value. More recently the 1990s productivity boom of new products has turned into a productivity bust, with fewer and more modest innovations, and flat or declining revenues for innovative firms as generics replace their former blockbuster products. This timely volume examines the economics of the biopharmaceutical industry, with eighteen chapters by leading academic health economists. Part one examines the economics of biopharmaceutical innovation including determinants of the costs and returns to new drug development; how capital markets finance R&D and how costs of financing the biopharmaceutical industry compare to financing costs for other industries; the effects of safety and efficacy regulation by the Food and Drug Administration (FDA) and of price and reimbursement regulation on incentives for innovation; and the role of patents and regulatory exclusivities. Part two examines the market for biopharmaceuticals with chapters on prices and reimbursement in the US, the EU, and other industrialized countries, and in developing countries. It looks at the optimal design of insurance for drugs and the effects of cost sharing on spending and on health outcomes; how to measure the value of pharmaceuticals using pharmacoeconomics, including theory, practical challenges, and policy issues; how to measure pharmaceutical price growth over time and recent evidence; empirical evidence on the value of pharmaceuticals in terms of health outcomes; promotion of pharmaceuticals to physicians and consumers; the economics of vaccines; and a review of the evidence on effects of mergers, acquisitions and alliances. Each chapter summarizes the latest insights from theory and recent empirical evidence, and outlines important unanswered questions and areas for future research. Based on solid economics, it is nevertheless written in terms accessible to the general reader. The book is thus recommended reading for academic economists and non-economists, and for those in industry and policy who wish to understand the economics of this fascinating industry.
Download or read book Pharmaceutical Market Access in Emerging Markets written by Güvenç Koçkaya and published by SEEd. This book was released on 2016-10-20 with total page 239 pages. Available in PDF, EPUB and Kindle. Book excerpt: The definition of Market Access was first reported by the World Trade Organization as “to open markets for trade and improve transparency, reciprocity, and non-discrimination in international trade”. Pharmaceutical Market Access is different and it could be defined as achieving the optimal price for a product or service and/or the maximum reimbursement for the approved target population with no restrictions on funding for the medical technology. By the way, Market Access is not only the market authorization, but it also includes overlapping activities like pricing, health technology assessment, formulary, and reimbursement. Market Access is one of the most important activities for pharmaceutical companies and emerging countries represent an important opportunity for launching new products. It was reported that the Compounded Average Growth Rate (CAGR) was 6.0% in the period 2011-2017, and expected sales exceeding 1.1 trillion USD by 2017 for emerging countries. Furthermore, CAGR 2008-2012 for recently launched pharmaceuticals were 9.8% for emerging countries and 1.5% for the top 8 developed countries. The Market Access processes in the most important emerging countries in the selected regions are defined in this book with the aim to help local experts, local government officers, headquarter managements, and everyone who want to learn more about healthcare system and health policies pathways of Market Access, mapping and structure of decision makers, challenges and catalyzers for Market Access in the emerging countries.
Download or read book Modern Methods of Clinical Investigation written by Institute of Medicine and published by National Academies Press. This book was released on 1990-02-01 with total page 241 pages. Available in PDF, EPUB and Kindle. Book excerpt: The very rapid pace of advances in biomedical research promises us a wide range of new drugs, medical devices, and clinical procedures. The extent to which these discoveries will benefit the public, however, depends in large part on the methods we choose for developing and testing them. Modern Methods of Clinical Investigation focuses on strategies for clinical evaluation and their role in uncovering the actual benefits and risks of medical innovation. Essays explore differences in our current systems for evaluating drugs, medical devices, and clinical procedures; health insurance databases as a tool for assessing treatment outcomes; the role of the medical profession, the Food and Drug Administration, and industry in stimulating the use of evaluative methods; and more. This book will be of special interest to policymakers, regulators, executives in the medical industry, clinical researchers, and physicians.
Download or read book Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies written by Mihajlo (Michael) Jakovljevic and published by Frontiers Media SA. This book was released on 2017-11-23 with total page 204 pages. Available in PDF, EPUB and Kindle. Book excerpt: This Research Topic was focused on provision of novel medical technologies worldwide keeping in mind financial sustainability challenge. An exemplary area certainly are oncology pharmaceuticals where prices have increased 10-fold in recent years leading to concerns on affordability. The objective of this collection of studies was to reveal some of the hidden underlying causes of unequal access to the medicines. Another core issue is the growing proportion of out-of-pocket health spending in many world regions. In line with the joint efforts of the editors and authors we received an exceptionally high response worldwide. This E-Book attracted a total of 37 self-standing research submissions out of which 32 ultimately passed external peer review and got published. Base affiliations of the authors spread across academia, pharmaceutical and medical device industry, governmental authorities and clinical medicine. Their home institutions were situated in fifteen different countries inclusive of Japan, Israel, Russia, USA, Germany, Italy, Netherlands, Austria, Spain, Malta, Serbia, Poland, Bulgaria, Hungary and Malaysia. We frankly believe that authors succeeded to cover important literature gaps referring to these world regions. We solicit global professional audience to put our efforts to the test and read this contribution to the health economics literature.
Download or read book Innovation and the Pharmaceutical Industry written by H. Tristram Engelhardt and published by M & M Scrivener Press. This book was released on 2014-05-14 with total page 253 pages. Available in PDF, EPUB and Kindle. Book excerpt: Innovation and the Pharmaceutical Industry: Critical Reflections on the Virtues of Profit examines the central role of profit in the development of pharmaceuticals, medical devices, and health care generally. Recent efforts to understand this role have often underestimated and even dismissed its importance, arguing for its replacement by other means and mechanisms. However, as the essays in this volume attest, it would be impossible to account adequately for the range of pharmaceuticals and medical devices that have become part of everyday medicine without recognizing that the depth and scope of innovations are tied not simply to altruism, a concern for the common good, or the pursuit of knowledge for its own sake, but crucially to the pursuit of private good and of individual profit. Balancing a concern for theory and practice, the analyses and evaluations provided in these essays touch directly on many of the most heated and important debates in pharmaceutical ethics, such as profit margins, corporate social responsibility, drug advertising, litigation, patents, and parallel trade. Reflecting critically on the problems and prospects of medical innovation, they invite a rethinking of the foundations of the bioethics and business ethics of the pharmaceutical and medical device industries by focusing on the long-term impact of policy decisions for human health and well-being.
Download or read book The Economics of US Healthcare Competition Innovation Regulation and Organizations written by and published by Stigler Center. This book was released on 2023-05-01 with total page 244 pages. Available in PDF, EPUB and Kindle. Book excerpt: This eBook was born out of a general diagnosis that the US healthcare sector is not only one of the most studied industries in economics but also one of the areas where the field can make the most progress. Indeed, the American healthcare industry has many features that are particularly attractive to economists. It is one of (if not the) largest sectors of the US economy, accounting for almost 20% of the national Gross Domestic Product and employing tens of millions of workers. Firms range from large conglomerates to small providers, and there is strong government-private sector interaction, with federal, state, and local governments shaping policy. The industry also has many failures, is undergoing tremendous change, and produces a wealth of data (even if not always perfectly formatted). The field, however, is far from saturated. Healthcare is such a complex and intricate sector, one where details matter so much that it is almost its own subfield of economics. These high barriers to entry prevent scholars from researching healthcare topics and weaken the cross-pollination of ideas, an increasing hallmark of many other areas. This is problematic, not the least, because any major advances in healthcare economics literally save lives (and billions of dollars). This project aimed to help lower these barriers and kick-start broader collaborations.
Download or read book Product Liability and the Economics of Pharmaceuticals and Medical Devices written by Steven Garber and published by RAND Corporation. This book was released on 1993 with total page 272 pages. Available in PDF, EPUB and Kindle. Book excerpt: This study examined the economic effects of product liability on firms producing drugs and medical devices. The study found that the liability system enhances the economic contributions of the industries in some ways.
Download or read book Issues in Pharmaceutical Economics written by Robert I. Chien and published by Free Press. This book was released on 1979 with total page 264 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Economics and Management in the Biopharmaceutical Industry in the USA written by Rachel Kim and published by Routledge. This book was released on 2018-12-17 with total page 142 pages. Available in PDF, EPUB and Kindle. Book excerpt: From a managerial perspective, the biopharmaceutical industry represents a competitive, fast-changing, intellectually-powered, innovation-driven sector. Many management scholars have studied this discontinuous era to make sense of strategic behavior and the cognition of firms and top managers. A past look at the biopharmaceutical industry provides answers to questions that most managers have. For example, what options do you have and what actions do you take when new firms enter your industry? In the 1970s, new biotechnology firms, funded by venture capitalists, appeared in the pharmaceutical industry with new knowledge. Successful pharmaceutical firms decided to collaborate with the new entrants and forge relationships to develop and create new, biotechnology engineered drugs. Thus, the addition of new biotechnology firms ushered in a new business model based on strategic alliances. Strategic alliances have now become an industrial norm called open innovation. The author looks at the historical path of the biopharmaceutical industry, particularly in the United States. While the pharmaceutical industry’s main contributions to society are substantial, there are pressing challenges the industry must face, such as an increase in infectious disease outbreaks or the global aging population, which require new types of care, additionally, mental health care and prescription painkiller addiction are persistent issues with economic repercussions to both federal and local governments. This book presents a holistic view of the biopharmaceutical industry, putting it in a historical context. It will best serve those who are eager to learn about this dynamic, fast-evolving industry and who would like to tackle current biopharmaceutical industry issues in the United States and be prepared for future industry challenges.
Download or read book Vietnam Healthcare Report written by Damjan P. DeNoble and published by Health Intelligence Asia LLC & Rubicon Strategy Group LLC. This book was released on 2015-03-13 with total page 123 pages. Available in PDF, EPUB and Kindle. Book excerpt: Over the course of several weeks in June and July of 2014, Rubicon Strategy Group conducted close to forty interviews with country managers of pharmaceutical and device companies, director level administrators in public and private hospitals, successful pharmacy and medical device shop owners, and entrepreneurs at the forefront of the cutting edge in the Vietnam healthcare market. In addition the team went out and conducted a validated survey questionnaire of consumers to judge their preference for particular products, and their preference for healthcare access options in the public and the private sector. The goal of this paper revealed itself in the course of compiling the data: to bring out insights from the front lines of the sales channels and the business models that make up the pharmaceutical and medical device markets in Vietnam. It is the hope of the authors that the information presented in this way can help inform sales strategies and the development of value add services for companies involved in the marketing and/or distribution of drug and medical device products in Vietnam. On the eve of a pair of large negotiations, - a free trade agreement negotiation between the EU and Vietnam, set to be finalized in October 2014, and the negotiation of the Trans Pacific Asean partnership – it was found that much of the conversation with healthcare system company representatives and sales channel participants turned to the issue of the public tender system as well as some of the hardships brought on by Vietnam’s ongoing healthcare market reform. Consequently, one section of this report is geared towards exploring how the policy and regulatory level challenges of the current tender process. However, in constructing this section it became clear that the value of the research conducted during this study is not simply in explaining the tender process as it is supposed to function at the policy level and the attendant issues that stem from that design, but also highlighting how the tender process impacts the decision making of pharmaceutical and medical device executives in-country, in real time, as well as how it impacts the various operators across sales channels. In other words, a core value of the study is necessarily attendant to its exploration of the strategies currently being employed by executives active in Vietnam’s healthcare market. In trying to present a picture of the ground-level impacts of policies and regulatory structures impacting Vietnam’s healthcare space, it is of course important to present a clear outline of the issues that the research revealed. At the same time, it became apparent to fully communicate the ground-level happenings as they related to the tender process, it was also helpful to present a series of case studies that would help add color and nuance to the issues clearly presented.